Repligen completes acquisition of BioLife Solutions
The acquisition adds complementary cell therapy field assets and a high-margin consumables business. Repligen intends to provide financial impact details in its third quarter 2026 earnings call.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed